Targeted delivery of anti-cancer drug sorafenib through magnetic solid lipid nanoparticles
Ciofani G., Grillone A., Mattoli V., Moscato S., Redolfi Riva E., Sacco R., Italian Institute of Technology, IT
The multi-kinase inhibitor sorafenib (tradename Nexavar®, Bayer) has been recently approved by the FDA for the treatment of non-resectable hepatocarcinoma and advanced renal carcinoma. Despite its proven survival benefit, sorafenib can lead to important side [...]